idiopathic pulmonary fibrosis/дијареја

Веза се чува у привремену меморију

Изаберите тип сортирања

Страна 1 од 22 резултати

Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Nintedanib is an important drug for the treatment of idiopathic pulmonary fibrosis (IPF). However, the drug is discontinued in some patients who present with diarrhea. In this study, we aimed to assess the drug continuation rate in patients who developed diarrhea during nintedanib

Colchicine versus prednisone as treatment of usual interstitial pneumonia.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To assess the results with colchicine and prednisone as initial single-drug therapy in patients with usual interstitial pneumonia (UIP). METHODS We reviewed the serial pulmonary function test results in 22 patients with typical clinical and high-resolution computed tomographic features of

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression by reducing annual lung function decline. OBJECTIVE To evaluate the results of a large cohort of IPF patients treated with nintedanib within a compassionate use

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Current clinical practice guidelines for idiopathic pulmonary fibrosis (IPF) conditionally recommend use of pirfenidone and nintedanib. However, an optimal treatment sequence has not been established, and the data of treatment sequence from pirfenidone to nintedanib are limited. This

Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE Idiopathic pulmonary fibrosis (IPF) is a progressive and deadly disease. The US Food and Drug Administration recently approved two medications for the treatment of IPF - pirfenidone and nintedanib. Given the limited clinical experience with these agents, a number of questions remain

The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease that primarily affects older individuals. Nintedanib, a tyrosine kinase inhibitor, has been approved for the treatment of IPF in several countries. The safety and tolerability of nintedanib have been

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by dyspnea and loss of lung function. METHODS Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS(®) trials, we characterized the safety and tolerability of nintedanib 150 mg

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Nintedanib represents an antifibrotic compound able to slow down disease progression of patients with idiopathic pulmonary fibrosis (IPF). To investigate the safety and efficacy of nintedanib in patients with IPF in a real-life setting. This was a multicentre, retrospective, observational, real-life

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Introduction: The safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) have been characterized using data from clinical trials. Methods:

Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background: We have often encountered adverse events requiring dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Objectives:

Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

In idiopathic pulmonary fibrosis (IPF), several factors may have a negative impact on the nutritional status, including an increased respiratory muscles load, release of inflammation mediators, the coexistence of hypoxemia, and physical inactivity. Nutritional abnormalities also have an impact on

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Clinical trials have shown that nintedanib 150 mg twice daily (bid) reduces disease progression in patients with idiopathic pulmonary fibrosis (IPF), with an adverse event profile that is manageable for most patients. Prior to the approval of nintedanib as a treatment for IPF in

Nintedanib for Idiopathic Pulmonary Fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To review the pharmacology, safety, and efficacy of nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). METHODS A literature search was conducted via PubMed using the MeSH term "idiopathic pulmonary fibrosis" combined with the key word "nintedanib." Additional online

A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Background

Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib for IPF has been previously proven in the INPULSIS^® and INPULSIS-On^® trials.

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Nausea and diarrhea are the most common adverse effects of nintedanib in patients with idiopathic pulmonary fibrosis (IPF). However, the clinical risk factors for these side effects remain unknown. In the present study, we investigated the characteristics of patients who developed gastrointestinal

Претходна
1
2
Следећи

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима